Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant Tumors

1 Apr 2024

Abstract excerpt

HER2 status determination is a necessary step for the proper choice of therapy and selection of patients for the targeted treatment of cancer. Targeted radiotracers such as radiolabeled DARPins provide a noninvasive and effective way for the molecular imaging of HER2 expression. This study aimed to evaluate tumor-targeting properties of three 99m Tc-labeled DARPin G3 variants containing Gly-Gly-Gly-Cys (G 3 C),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Radiopharmaceutical Chemistry and Applications

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38557163
DOI: 10.1021/acs.molpharmaceut.3c01173

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins G3 for the 99mTc-Based Imaging of HER2-Expressing Malignant TumorsPMID 38557163Read ↗

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in CancerSemantic proximity Read ↗

Comparative Preclinical Evaluation of Peptide-Based Chelators for Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in CancerSemantic proximity Read ↗

Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting PropertiesSemantic proximity Read ↗

Designed Ankyrin Repeat Proteins as Her2 Targeting Domains in Chimeric Antigen Receptor-Engineered T CellsSemantic proximity Read ↗

Selection and Characterization of Her2 Binding-designed Ankyrin Repeat ProteinsSemantic proximity Read ↗

Synthesis and Comparative Evaluation of 177 Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probesSemantic proximity Read ↗

Preclinical Positron Emission Tomography Imaging of B7–H3 Expression Using Affibody Molecules Labeled with Gallium-68Semantic proximity Read ↗

Targeting HER3 for cancer treatment: a new horizon for an old targetSemantic proximity Read ↗

Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Anti-Tumor Activity in Colorectal CancerSemantic proximity Read ↗

New Developments in Peptide Receptor Radionuclide TherapySemantic proximity Read ↗

Anti-Cancer Immune Priming with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3Semantic proximity Read ↗

68Ga-Labeled Glycopeptides as Effective Tools for Liver Function ImagingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.